Locally Advanced or Metastatic Solid Tumors Clinical Trial
Official title:
A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
This is a Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors. Number of subjects is about 27-36 subjects. ;
| NCT number | NCT05205109 |
| Study type | Interventional |
| Source | Antengene Corporation |
| Contact | Julia Leng |
| Phone | +61(0)4-1181-8616 |
| [email protected] | |
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Start date | February 28, 2022 |
| Completion date | August 30, 2024 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04564417 -
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04511845 -
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
|
Phase 1 | |
| Active, not recruiting |
NCT04128423 -
Study of AMV564 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05012618 -
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
|
Phase 1 | |
| Completed |
NCT03736850 -
Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05137275 -
Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT01021748 -
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
|
Phase 1 | |
| Completed |
NCT01713036 -
Oral Bioavailability and Mass Balance Trial With Pimasertib
|
Phase 1 | |
| Recruiting |
NCT05116709 -
Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05102214 -
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05360381 -
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03478995 -
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03150810 -
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03565991 -
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
|
Phase 2 | |
| Completed |
NCT02722954 -
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT02478099 -
MPDL3280A-treatment-IST-UMCG
|
Phase 2 | |
| Recruiting |
NCT04996121 -
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 |